Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464497 | 0.99 | HPGD (0.52) | HPGDKCNH2HRH3SMYD3MGLL | |
| SCHEMBL31464521 | 0.92 | SMYD3 (0.52) | HPGDKCNH2HRH3SMYD3MGLL | |
| SCHEMBL31464602 | 0.91 | PKM (0.48) | HPGDSMYD3MGLLGRM2 | |
| SCHEMBL31464433 | 0.91 | SMYD3 (0.51) | HPGDKCNH2HRH3SMYD3MGLL | |
| SCHEMBL31464555 | 0.90 | ALOX5AP (0.46) | SMYD3MGLLMAPKAPK2FASN | |
| SCHEMBL31464401 | 0.89 | FASN (0.46) | HPGDKCNH2HRH3SMYD3MGLL | |
| SCHEMBL31464760 | 0.86 | SMYD3 (0.49) | SMYD3MGLLMAPKAPK2RORC | |
| SCHEMBL31464631 | 0.85 | CCNT1 (0.44) | HRH3SMYD3MGLLMAPKAPK2 | |
| SCHEMBL31464436 | 0.85 | P2RX7 (0.45) | KCNH2HRH3SMYD3MGLLMAPKAPK2 | |
| SCHEMBL31464831 | 0.85 | HPGD (0.47) | HPGDKCNH2HRH3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | HPGD 3528/4885KCNH2 4664/4885HRH3 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.